Wen‐Hsuan Wendy Lin

Wen‐Hsuan Wendy Lin

Auto-generated profile, based on publicly available information

Wen‐Hsuan Wendy Lin

Columbia University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2020 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SWStuart P. Weisberg
Stuart P. Weisberg
TCThomas J. Connors
Thomas J. Connors
YZYun Zhu
Yun Zhu
MBMatthew R. Baldwin
Matthew R. Baldwin
WLWen-Hsuan Lin
Wen-Hsuan Lin
DFDonna L. Farber
Donna L. Farber
Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are associated with age1,2. Adults develop respiratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe form, while children are largely spared from respiratory illness but can develop a life-threatening multisystem inflammatory syndrome (MIS-C)3,4,5. Here, we show distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating IgG antibodies specific for the S protein but not the N protein. Moreover, children with and without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children independent of whether they develop MIS-C, with implications for developing age-targeted strategies for testing and protecting the population.

1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MOMax R. O’dOnnell
Max R. O’dOnnell
BGBeatriz Grinsztejn
Beatriz Grinsztejn
MCMatthew J. Cummings
Matthew J. Cummings
JJJessica E. Justman
Jessica E. Justman
MLMatthew R. Lamb
Matthew R. Lamb
ILIan Lipkin
Ian Lipkin
BACKGROUND. Although convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited. METHODS. We conducted a randomized, double-blind, controlled trial among adults hospitalized with severe and critical COVID-19 at 5 sites in New York City (USA) and Rio de Janeiro (Brazil). Patients were randomized 2:1 to receive a single transfusion of either convalescent plasma or normal control plasma. The primary outcome was clinical status at 28 days following randomization, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population. RESULTS. Of 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to receive normal control plasma. At 28 days, no significant improvement in the clinical scale was observed in participants randomized to convalescent plasma (OR 1.50, 95% confidence interval [CI] 0.83–2.68, P = 0.180). However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22–0.91, P = 0.034). The median titer of anti–SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80–1:320). In a subset of nasopharyngeal swab samples from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. CONCLUSION. In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in day 28 clinical status. However, convalescent plasma was associated with significantly improved survival. A possible explanation is that survivors remained hospitalized at their baseline clinical status. TRIAL REGISTRATION. ClinicalTrials.gov, NCT04359810. FUNDING. Amazon Foundation, Skoll Foundation.

6 December 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SNSimone A. Nish
Simone A. Nish
KZKyra Zens
Kyra Zens
RKRadomir Kratchmarov
Radomir Kratchmarov
WLWen-Hsuan W. Lin
Wen-Hsuan W. Lin
WAWilliam C. Adams
William C. Adams
SRSteven L. Reiner
Steven L. Reiner
Upon infection, an activated CD4+ T cell produces terminally differentiated effector cells and renews itself for continued defense. In this study, we show that differentiation and self-renewal arise as opposing outcomes of sibling CD4+ T cells. After influenza challenge, antigen-specific cells underwent several divisions in draining lymph nodes (LN; DLNs) while maintaining expression of TCF1. After four or five divisions, some cells silenced, whereas some cells maintained TCF1 expression. TCF1-silenced cells were T helper 1–like effectors and concentrated in the lungs. Cells from earliest divisions were memory-like and concentrated in nondraining LN. TCF1-expressing cells from later divisions in the DLN could self-renew, clonally yielding a TCF1-silenced daughter cell as well as a sibling cell maintaining TCF1 expression. Some TCF1-expressing cells in DLNs acquired an alternative, follicular helper-like fate. Modeled differentiation experiments in vitro suggested that unequal PI3K/mechanistic target of rapamycin signaling drives intraclonal cell fate heterogeneity. Asymmetric division enables self-renewal to be coupled to production of differentiated CD4+ effector T cells during clonal selection.

1 April 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WLWen-Hsuan W. Lin
Wen-Hsuan W. Lin
EMEileen Moran
Eileen Moran
RARobert J. Adams
Robert J. Adams
RSRobert E. Sievers
Robert E. Sievers
DHDebra Hauer
Debra Hauer
DGDiane Griffin
Diane Griffin
Wild-type measles virus replicates better in immune cells and induces more durable antibody responses in macaques than the live-attenuated measles virus vaccine.

13 February 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
ANAshley N. Nelson
Ashley N. Nelson
WLWen-Hsuan W. Lin
Wen-Hsuan W. Lin
RSRupak Shivakoti
Rupak Shivakoti
NPNicole E. Putnam
Nicole E. Putnam
LMLisa Mangus
Lisa Mangus
DGDiane Griffin
Diane Griffin
Recovery from measles results in life-long protective immunity. To understand induction of long-term immunity, rhesus macaques were studied for 6 months after infection with wild-type measles virus (MeV). Infection caused viremia and rash, with clearance of infectious virus by day 14. MeV RNA persisted in PBMCs for 30–90 days and in lymphoid tissue for 6 months most often in B cells but was rarely detected in BM. Antibody with neutralizing activity and binding specificity for MeV nucleocapsid (N), hemagglutinin (H), and fusion proteins appeared with the rash and avidity matured over 3–4 months. Lymph nodes had increasing numbers of MeV-specific antibody-secreting cells (ASCs) and germinal centers with late hyalinization. ASCs appeared in circulation with the rash and continued to appear along with peripheral T follicular helper cells for the study duration. ASCs in lymph nodes and PBMCs produced antibody against both H and N, with more H-specific ASCs in BM. During days 14–21, 20- to 100-fold more total ASCs than MeV-specific ASCs appeared in circulation, suggesting mobilization of preexisting ASCs. Therefore, persistence of MeV RNA in lymphoid tissue was accompanied by continued germinal center formation, ASC production, avidity maturation, and accumulation of H-specific ASCs in BM to sustain neutralizing antibody and protective immunity.

13 January 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CMChristine S. Moon
Christine S. Moon
CRClara Reglero
Clara Reglero
JCJose R. Cortes
Jose R. Cortes
SQS. Aidan Quinn
S. Aidan Quinn
SASilvia Alvarez
Silvia Alvarez
AFAdolfo A. Ferrando
Adolfo A. Ferrando